製药、生物技术和诊断产业的併购交易（2021-2026）

全球生命科学产业併购策略基准分析

"製药、生物技术和诊断产业的併购交易（2021-2026）" 报告对全球生命科学产业的併购活动进行了全面分析。本报告专为企业发展、业务拓展、投资和策略领域的专业人士设计，深入剖析了企业如何建立併购交易以及如何就交易背后的财务条款进行谈判。

这份经过全面修订和更新的报告分析了2021年1月至2026年3月期间宣布的2500多笔併购交易，全面展现了製药、生物技术和诊断公司的收购活动。

每笔交易都包含指向详细线上合约记录的链接，并且在条件允许的情况下，还会提供提交给监管机构的原始合约。透过整合全面的合约资料、财务基准和合约存取权限，本报告提供了宝贵的见解，帮助您评估收购机会、衡量合约价值并了解产业整合策略。

主要优势

• 显着缩短研究时间

在一个集中式资源中存取超过2500笔併购交易。无需再搜寻多个资料库、新闻稿和监管文件。

• 收购结构与估值基准分析

了解製药、生技和诊断设备公司如何建构收购方案，包括现金协议、股权协议和混合结构。

• 自信分析合约价值

审查已揭露的合约金额和财务条款，并比较类似交易中的收购价格和合约结构。

• 查阅实际合约文件

如有需要，请参考向美国证券交易委员会 (SEC) 提交的併购协议，以深入了解实际协议背后的详细合约条款。

• 辨识最活跃的收购方

辨识出引领产业重组的关键参与者，并分析其收购策略。

• 追踪产业整合趋势

分析各公司、治疗领域和技术领域的併购活动，以了解生命科学产业的演变。

回报内容

2021年以来併购交易趋势分析

併购交易结构概述

基于已揭露交易价值的重大收购交易回顾

最活跃的收购者和交易撮合者简介

依公司、治疗领域、技术类型和行业细分市场进行的详细交易分析

2021年以来已公布的併购交易综合目录

线上交易记录和交易文件连结（如有）

基于实际合约的尽职调查见解

本报告允许使用者评估关键合约条款，例如：

• 资产和公司收购结构
• 收购价格以及付款方式
• 智慧财产权转让条款
• 获利支付结构与有条件付款
• 业务整合责任范围
• 交割条件与终止条款
• 查阅实际合约能够深入了解公司间谈判的详细条款。这些资讯很少在新闻稿或传统合约资料库中披露。
• 本报告的重要性
• 对于製药和生技公司而言，併购是拓展产品线、取得创新技术和加速成长的关键策略。生命科学产业每年都会出现大规模的併购活动，各公司都在寻求策略性收购，以增强其产品组合和能力。 本报告结合了全面的收购数据、合约基准分析以及对实际合约文件的查阅，为评估收购机会、了解行业整合趋势以及进行更有效的谈判提供了必要的洞察。

目录

摘要整理

第一章：引言

第二章：併购合约趋势

• 引言
• 合併与收购的差异
• 2021年以来併购合约趋势
  • 2021年以来併购合约数（年度）
  • 2021年以来各行业的併购合约状况
  • 2021年以来各治疗领域的併购合约
  • 2021年以来最活跃公司的併购合约
• 主要併购趋势
• 新的收购：是否有收购选择？
• 何时进行併购可行
• 併购协议的特征
  • 併购作为IPO的替代方案
• 包含併购要素的合伙协议
  • 合伙作为併购的预备阶段
  • 合伙协议中的股权部分
  • 从合伙到收购的过渡
  • 然而，併购并非总是首选路径
• 大型製药公司的大规模合併－末日将至？
  • 强生公司透过併购实现成长
  • 诺华公司透过併购实现成长
• 透过併购获取创新
  • 大药厂收购中小企业
  • 中小型生物製药公司－利用併购
  • 利用併购组成公司
  • 生技公司合併的兴起
• 私募股权在併购中的新角色
• 併购协议的执行
• 合资企业作为併购的替代方案
• 生物製药併购的未来

第三章 併购协议结构概述

• 引言
• 纯收购协议与多组分收购协议
• 纯併购协议结构
• 作为更广泛合作协议一部分的收购
• 合併协议

第四章 - 重大併购交易

• 引言
• 以价值排名的顶级併购交易

第五章 - 最活跃的25家併购公司

• 引言
• 最活跃的25家併购公司

第六章 - 2021年以来的併购交易目录

• 引言
• 2021年以来签订的併购交易
• 交易目录
• 依公司（AZ）分类的併购交易目录
• 依治疗领域分类的併购交易目录
• 交易类型定义
• 关于我们研究公司
• 当前合作伙伴关係
• 当前交易
• 来自 Current Partnership 的最新报告标题

Benchmark Acquisition Strategies Across the Global Life Sciences Industry

The Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2021-2026 report provides a comprehensive analysis of acquisition activity across the global life sciences sector. Designed for corporate development, business development, investment, and strategy professionals, the report delivers detailed insight into how companies structure mergers and acquisitions and negotiate the financial terms behind these transactions.

Fully revised and updated, the report analyzes 2,500+ M&A agreements announced between January 2021 and March 2026, offering an extensive view of acquisition activity across pharmaceutical, biotechnology, and diagnostics companies.

Each transaction links to a detailed online deal record and, where available, the original contract documents filed with regulators. By combining comprehensive deal data, financial benchmarking, and contract access, the report provides valuable intelligence for evaluating acquisition opportunities, benchmarking transaction values, and understanding industry consolidation strategies.

Key Benefits

• Save Significant Research Time

Access over 2,500 M&A deals in one consolidated resource, eliminating the need to search multiple databases, press releases, and regulatory filings.

• Benchmark Acquisition Structures and Valuations

Understand how pharmaceutical, biotechnology, and diagnostics companies structure acquisitions, including cash transactions, equity deals, and hybrid structures.

• Analyze Transaction Values with Confidence

Review disclosed deal values and financial terms to benchmark acquisition prices and transaction structures across comparable deals.

• Access Real Contract Documents

Where available, explore SEC-filed merger and acquisition agreements, providing insight into the detailed contractual provisions behind real transactions.

• Identify the Most Active Acquirers

Discover which companies are leading consolidation activity and analyze their acquisition strategies.

• Track Industry Consolidation Trends

Analyze M&A activity across companies, therapeutic areas, and technology sectors to understand how the life sciences industry is evolving.

What's Included in the Report

Analysis of M&A dealmaking trends since 2021

Overview of merger and acquisition transaction structures

Review of leading acquisitions by disclosed deal value

Profiles of the most active acquirers and dealmakers

Detailed analysis of deals by company, therapeutic area, technology type, and industry segment

A comprehensive directory of M&A transactions announced since 2021

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual merger and acquisition contracts, the report enables users to evaluate key transaction provisions such as:

• Asset and company acquisition structures
• Purchase price and payment mechanisms
• Intellectual property transfer provisions
• Earn-out structures and contingent payments
• Operational integration responsibilities
• Transaction closing conditions and termination clauses
• Access to real agreements provides insight into the detailed terms negotiated between companies-information rarely disclosed in press releases or traditional deal databases.
• Why This Report Matters
• Mergers and acquisitions are a critical strategy for pharmaceutical and biotechnology companies seeking to expand pipelines, acquire innovative technologies, and accelerate growth. The life sciences industry experiences significant M&A activity each year as companies pursue strategic acquisitions to strengthen their portfolios and capabilities.
• By combining comprehensive acquisition data, transaction benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate acquisition opportunities, understand industry consolidation trends, and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in M&A dealmaking

• 2.1. Introduction
• 2.2. Difference between merger and acquisition deals
• 2.3. Trends in M&A deals since 2021
  • 2.3.1. M&A dealmaking by year since 2021
  • 2.3.2. M&A dealmaking by industry sector since 2021
  • 2.3.3. M&A dealmaking by therapy area since 2021
  • 2.3.4. M&A dealmaking by most active company since 2021
• 2.4. Key M&A trends
• 2.5. Option to acquire the new acquisition?
• 2.6. When M&A can be useful
• 2.7. Attributes of M&A deals
  • 2.7.1. M&A as an alternative to IPO
• 2.8. Partnering deals with M&A component
  • 2.8.1. Partnering as a precursor to M&A
  • 2.8.2. Equity as part of partnering deal
  • 2.8.3. Conversion of partnership to acquisition
  • 2.8.4. But M&A is not always the route followed
• 2.9. Big pharma mega mergers - are we at the end of the road?
  • 2.9.1. Growth of Johnson & Johnson through M&A
  • 2.9.2. Growth of Novartis through M&A
• 2.10. Accessing innovation through M&A
  • 2.10.1. Big pharma acquisitions of small companies
  • 2.10.2. Medium and small biopharma - use of M&A
  • 2.10.3. Using M&A to build a company
  • 2.10.4. Emergence of biotech-biotech mergers
• 2.11. The emerging role of private equity in M&A
• 2.12. Implementing M&A transactions
• 2.13. Joint ventures as alternative to M&A
• 2.14. The future of M&A in biopharma

Chapter 3 - Overview of M&A deal structure

• 3.1. Introduction
• 3.2. Pure versus multi-component acquisition deals
• 3.3. Pure M&A agreement structure
• 3.4. Acquisition as part of a wider alliance agreement
• 3.5. Merger agreements

Chapter 4 - Leading M&A deals

• 4.1. Introduction
• 4.2. Top M&A deals by value

Chapter 5 - Top 25 most active M&A dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active M&A dealmakers

Chapter 6 - M&A contract directory since 2021

• 6.1. Introduction
• 6.2. M&A deals with contracts since 2021
• Deal Directory
• Deal Directory - M&A deals by company A-Z
• Deal Directory - M&A deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of merger and acquisition
• Figure 2: Trends in M&A deal announcements
• Figure 3: M&A deals by industry sector
• Figure 4: M&A deals by therapy area
• Figure 5: Top 50 most active M&A dealmakers
• Figure 6: Key recent M&A trends
• Figure 7: Situations where M&A can prove useful
• Figure 8: Recent partnering deals involving equity participation in the licensor
• Figure 9: Equity investments converting to acquisitions
• Figure 10: Issues in implementing M&A agreements
• Figure 11: Future trends in M&A in biopharma
• Figure 12: Components of the acquisition deal structure
• Figure 13: Components of the merger deal structure
• Figure 14: Top M&A deals by value
• Figure 15: Most active M&A dealmakers